Ahmad Masri Profile picture
@OHSUCardio | #HCM #Amyloid #Fabry #LVH #DCM #Cardiomyopathies #Cardiogenetics #Echofirst #WhyCMR #CVNuc #RCTs | Views are mine & not medical advice
May 13 8 tweets 3 min read
The third presentation is by Greg Lewis focusing on the exercise response in #SEQUOIA #HCM
#HeartFailure2024 #CardioTwitter
Image The exercise story and limitations in HCM

Image
Image
Image
Sep 4, 2022 7 tweets 4 min read
A different tale of making use of amyloids - the good side
#ISA_2022 Examples of good functional amyloids produced in nature #ISA_2022
Sep 4, 2022 16 tweets 7 min read
Dr. Merlini talks on AL amyloidosis as a model for treating other amyloid disorders #ISA_2022
Light chains cardiotoxicity in many studies
Sep 4, 2022 9 tweets 4 min read
The keynote address by Dr. Weyand discussing aging of the immune system #ISA_2022 The aging nation
Dec 19, 2020 4 tweets 3 min read
Preclinical and phase I data for $AKCA-TTR-LRx (second generation inotersen, ASO conjugated with GalNAc), currently being tested in CARDIO-TTRansform, the largest #ATTR #Amyloidosis trial to date. Tafamidis allowed without restrictions.

onlinelibrary.wiley.com/doi/epdf/10.10…

#cardiotwitter Cojugation with GalNAc increased potency by 20-30x, allowing lower dose, lower frequency, less AE
Jun 20, 2020 13 tweets 7 min read
Thread/

There are many new exciting trials in transthyretin #amyloidosis – as we continue to enroll patients in the CARDIO-TTRansform trial, I thought I would highlight some of these trials in ATTR-CM

clinicaltrials.gov/ct2/show/NCT04…

#cardiotwitter Image If you recall, 2 main approaches to treating ATTR #amyloidosis with approved drugs (figure credit @frederickruberg @maz_hanna )
1)Stabilizers: bind to the TTR tetramer to stabilize it. #tafamidis , AG-10, diflunisal
2)Silencers: Inotersen and Patisiran Image
Aug 7, 2019 11 tweets 4 min read
Do you know the name of this sign on #echofirst?
#Cardiotwitter #ACCFIT In 2006, Pieroni et al called this the "Binary Sign". They identified this myocardium appearance in 40 patients with Fabry's disease. When compared to patients with HCM, HTN, and healthy subjects, the sign had 94% sensitivity and 100% specificity. ( )ncbi.nlm.nih.gov/pubmed/16631007
Dec 23, 2018 13 tweets 7 min read
A thread.
So the @US_FDA @SGottliebFDA issued a warning re: Fluoroquinolones (FLQ) and aortic dissection (AD) or aneurysm (AA). Do FLQs cause AD/AA? Not really. Is there an association? Maybe. Let’s go throw the evidence and you can decide for yourself.
#CardioTwitter #MedEd 1/ Why was this association even studied? FLQ are known to be associated with Achilles tendon rupture, tendinopathy, retinal detachment. How? 1)decrease collagen synthesis and increase MMP (especially 2, 9) activity (among others). Aorta is affected by these processes
Nov 29, 2018 8 tweets 13 min read
A great case of bicuspid-associated aortopathy.
How common is aortic dissection in BAV? To date, many surgeons operate on patients with dilated aortas in the 4.5-5.0 cm range without concomitant severe valve disease. But, how about the evidence so far?
#cardiotwitter #MedEd 1) IRAD had 1.9% BAV patients in a 2006 report (out of 303 type A dissections)
ncbi.nlm.nih.gov/pubmed/16820599
Sep 27, 2018 18 tweets 10 min read
1/ A long thread on LifeVest. I promise it will be entertaining. If you find any inaccuracies please let me know.

Paper of VEST published here - will discuss background to WCD and #VEST but not the trial itself nejm.org/doi/full/10.10… 2/ In 2001, FDA gave approval to Lifecor for the first WCD. Later Lifecor was acquired by Zoll (2004 agreement, 2006 acquisition). Zoll maintains a registry for prescribed LifeVests. But lets go back to the FDA approval process.